NCT00216723 - Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder | Biotech Hunter

Enrollment

3,000

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

December 31, 2009

Conditions

SchizophreniaBipolar Disorder

Interventions

DRUG

Aripiprazole

"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"

Trial Locations (2)

Unknown

Asan Medical Center, Seoul

Samsung Medical Center, Seoul